Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 77
Filtrer
1.
Immunol Lett ; 267: 106863, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38705482

RÉSUMÉ

Diabetes mellitus (DM) is a chronic systemic disease characterized by a multifactorial nature, which may lead to several macro and microvascular complications. Diabetic retinopathy (DR) is one of the most severe microvascular complications of DM, which can result in permanent blindness. The mechanisms involved in the pathogenesis of DR are multiple and still poorly understood. Factors such as dysregulation of vascular regeneration, oxidative and hyperosmolar stress in addition to inflammatory processes have been associated with the pathogenesis of DR. Furthermore, compelling evidence shows that components of the immune system, including the complement system, play a relevant role in the development of the disease. Studies suggest that high concentrations of mannose-binding lectin (MBL), an essential component of the complement lectin pathway, may contribute to the development of DR in patients with DM. This review provides an update on the possible role of the complement system, specifically the lectin pathway, in the pathogenesis of DR and discusses the potential of MBL as a non-invasive biomarker for both, the presence and severity of DR, in addition to its potential as a therapeutic target for intervention strategies.


Sujet(s)
Marqueurs biologiques , Rétinopathie diabétique , Lectine liant le mannose , Humains , Rétinopathie diabétique/immunologie , Rétinopathie diabétique/étiologie , Rétinopathie diabétique/métabolisme , Rétinopathie diabétique/diagnostic , Lectine liant le mannose/métabolisme , Animaux , Voie des lectines , Prédisposition aux maladies , Activation du complément/immunologie
2.
Int J Mol Sci ; 24(9)2023 Apr 27.
Article de Anglais | MEDLINE | ID: mdl-37175628

RÉSUMÉ

Diabetic retinopathy causes progressive and irreversible damage to the retina through activation of inflammatory processes, overproduction of oxidative species, and glial reactivity, leading to changes in neuronal function and finally ischemia, edema, and hemorrhages. Current treatments are invasive and mostly applied at advanced stages, stressing the need for alternatives. To this end, we tested two unconventional and potentially complementary non-invasive treatment options: Photobiomodulation, the stimulation with near-infrared light, has shown promising results in ameliorating retinal pathologies and insults in several studies but remains controversial. Boldine, on the other hand, is a potent natural antioxidant and potentially useful to prevent free radical-induced oxidative stress. To establish a baseline, we first evaluated the effects of diabetic conditions on the retina with immunofluorescence, histological, and ultrastructural analysis in two diabetes model systems, obese LepRdb/db mice and organotypic retinal explants, and then tested the potential benefits of photobiomodulation and boldine treatment in vitro on retinal explants subjected to high glucose concentrations, mimicking diabetic conditions. Our results suggest that the principal subcellular structures affected by these conditions were mitochondria in the inner segment of photoreceptors, which displayed morphological changes in both model systems. In retinal explants, lactate metabolism, assayed as an indicator of mitochondrial function, was altered, and decreased photoreceptor viability was observed, presumably as a consequence of increased oxidative-nitrosative stress. The latter was reduced by boldine treatment in vitro, while photobiomodulation improved mitochondrial metabolism but was insufficient to prevent retinal structural damage caused by high glucose. These results warrant further research into alternative and complementary treatment options for diabetic retinopathy.


Sujet(s)
Diabète , Rétinopathie diabétique , Souris , Animaux , Rétinopathie diabétique/traitement médicamenteux , Rétinopathie diabétique/métabolisme , Rétine/métabolisme , Antioxydants/pharmacologie , Stress oxydatif , Glucose/métabolisme , Diabète/métabolisme
3.
Int J Mol Sci ; 24(6)2023 Mar 11.
Article de Anglais | MEDLINE | ID: mdl-36982479

RÉSUMÉ

Despite the obvious morphological differences in the visual system, zebrafish share a similar architecture and components of the same embryonic origin as humans. The zebrafish retina has the same layered structure and cell types with similar metabolic and phototransduction support as humans, and is functional 72 h after fertilization, allowing tests of visual function to be performed. The zebrafish genomic database supports genetic mapping studies as well as gene editing, both of which are useful in the ophthalmological field. It is possible to model ocular disorders in zebrafish, as well as inherited retinal diseases or congenital or acquired malformations. Several approaches allow the evaluation of local pathological processes derived from systemic disorders, such as chemical exposure to produce retinal hypoxia or glucose exposure to produce hyperglycemia, mimicking retinopathy of prematurity or diabetic retinopathy, respectively. The pathogenesis of ocular infections, autoimmune diseases, or aging can also be assessed in zebrafish larvae, and the preserved cellular and molecular immune mechanisms can be assessed. Finally, the zebrafish model for the study of the pathologies of the visual system complements certain deficiencies in experimental models of mammals since the regeneration of the zebrafish retina is a valuable tool for the study of degenerative processes and the discovery of new drugs and therapies.


Sujet(s)
Rétinopathie diabétique , Danio zébré , Animaux , Humains , Nouveau-né , Larve/métabolisme , Rétine/métabolisme , Vision , Rétinopathie diabétique/métabolisme , Mammifères
4.
Biol Res ; 55(1): 14, 2022 Mar 26.
Article de Anglais | MEDLINE | ID: mdl-35346383

RÉSUMÉ

BACKGROUND: Diabetic retinopathy (DR) is a specific microvascular complication arising from diabetes, and its pathogenesis is not completely understood. tRNA-derived stress-induced RNAs (tiRNAs), a new type of small noncoding RNA generated by specific cleavage of tRNAs, has become a promising target for several diseases. However, the regulatory function of tiRNAs in DR and its detailed mechanism remain unknown. RESULTS: Here, we analyzed the tiRNA profiles of normal and DR retinal tissues. The expression level of tiRNA-Val was significantly upregulated in DR retinal tissues. Consistently, tiRNA-Val was upregulated in human retinal microvascular endothelial cells (HRMECs) under high glucose conditions. The overexpression of tiRNA-Val enhanced cell proliferation and inhibited cell apoptosis in HRMECs, but the knockdown of tiRNA-Val decreased cell proliferation and promoted cell apoptosis. Mechanistically, tiRNA-Val, derived from mature tRNA-Val with Ang cleavage, decreased Sirt1 expression level by interacting with sirt1 3'UTR, leading to the accumulation of Hif-1α, a key target for DR. In addition, subretinal injection of adeno-associated virus to knock down tiRNA-Val in DR mice ameliorated the symptoms of DR. CONCLUSION: tiRNA-Val enhance cell proliferation and inhibited cell apoptosis via Sirt1/Hif-1α pathway in HRMECs of DR retinal tissues.


Sujet(s)
Diabète , Rétinopathie diabétique , Animaux , Diabète/génétique , Diabète/métabolisme , Diabète/anatomopathologie , Rétinopathie diabétique/génétique , Rétinopathie diabétique/métabolisme , Rétinopathie diabétique/anatomopathologie , Cellules endothéliales , Souris , Néovascularisation pathologique/génétique , Rétine/métabolisme , Rétine/anatomopathologie , Sirtuine-1/métabolisme
5.
Biol. Res ; 55: 14-14, 2022. ilus
Article de Anglais | LILACS | ID: biblio-1383916

RÉSUMÉ

BACKGROUND: Diabetic retinopathy (DR) is a specific microvascular complication arising from diabetes, and its pathogenesis is not completely understood. tRNA-derived stress-induced RNAs (tiRNAs), a new type of small noncoding RNA generated by specific cleavage of tRNAs, has become a promising target for several diseases. However, the regulatory function of tiRNAs in DR and its detailed mechanism remain unknown. RESULTS: Here, we analyzed the tiRNA profiles of normal and DR retinal tissues. The expression level of tiRNA-Val was significantly upregulated in DR retinal tissues. Consistently, tiRNA-Val was upregulated in human retinal microvascular endothelial cells (HRMECs) under high glucose conditions. The overexpression of tiRNA-Val enhanced cell proliferation and inhibited cell apoptosis in HRMECs, but the knockdown of tiRNA-Val decreased cell proliferation and promoted cell apoptosis. Mechanistically, tiRNA-Val, derived from mature tRNA-Val with Ang cleavage, decreased Sirt1 expression level by interacting with sirt1 3'UTR, leading to the accumulation of Hif-1α, a key target for DR. In addition, subretinal injection of adeno-associated virus to knock down tiRNA-Val in DR mice ameliorated the symptoms of DR. CONCLUSION: tiRNA-Val enhance cell proliferation and inhibited cell apoptosis via Sirt1/Hif-1α pathway in HRMECs of DR retinal tissues.


Sujet(s)
Animaux , Souris , Diabète/génétique , Diabète/métabolisme , Diabète/anatomopathologie , Rétinopathie diabétique/génétique , Rétinopathie diabétique/métabolisme , Rétinopathie diabétique/anatomopathologie , Rétine/métabolisme , Rétine/anatomopathologie , Cellules endothéliales , Sirtuine-1/métabolisme , Néovascularisation pathologique/génétique
6.
Sci Rep ; 11(1): 23981, 2021 12 14.
Article de Anglais | MEDLINE | ID: mdl-34907265

RÉSUMÉ

This study aimed to analyze the concentrations of VEGF, b-FGF, TNF, interleukin (IL)-1, IL-6, IL-8, IL-10, and IL-12 in the aqueous humor of patients with diabetic macular edema with and without peripheral retinal ischemia and to ascertain the changes in the levels of these molecules during treatment with ranibizumab. A therapeutic, prospective, randomized interventional study was carried out. Twenty-four eyes from 24 patients were studied and divided into 3 groups. Group 1 (9 eyes) included patients with diabetic macular edema without peripheral ischemia. Group 2 (10 eyes) included patients with diabetic macular edema with peripheral ischemia. Group 3 (5 eyes), the control group, included patients without systemic and/or eye diseases. Patients in Groups 1 and 2 received 3 intravitreal injections of 2 mg/0.05 ml ranibizumab at an interval of approximately 30 days. Before administering the injections, the aqueous humor was collected. In the control group, aqueous humor was collected before facetectomy. During treatment, the median IL-6 concentration significantly increased in Group 1 but showed a slight but not significant decrease in Group 2. Interleukin 8 levels were significantly different at the end of treatment compared to the beginning in Groups 1 and 2. TNF, IL-1, IL-10, and IL-12 levels were practically unchanged in both groups. VEGF was significantly reduced at the end of the study in Groups 1 and 2. B-FGF was not detected in most of the studied patients, and in those with detectable levels, there was no significant variation. There was a significant increase in the median level of interleukin 6 in the group without ischemia and a significant decrease in VEGF in both groups. The cytokines TNF, IL-1, IL-10, and IL-12 did not show significant variation.


Sujet(s)
Humeur aqueuse , Cytokines/métabolisme , Rétinopathie diabétique , Oedème maculaire , Ranibizumab/administration et posologie , Sujet âgé , Humeur aqueuse/imagerie diagnostique , Humeur aqueuse/métabolisme , Rétinopathie diabétique/imagerie diagnostique , Rétinopathie diabétique/traitement médicamenteux , Rétinopathie diabétique/métabolisme , Humains , Injections intravitréennes , Oedème maculaire/imagerie diagnostique , Oedème maculaire/traitement médicamenteux , Oedème maculaire/métabolisme , Mâle , Adulte d'âge moyen , Études prospectives
7.
Mol Med Rep ; 24(2)2021 Aug.
Article de Anglais | MEDLINE | ID: mdl-34184090

RÉSUMÉ

Retinal neuron apoptosis is a key component of diabetic retinopathy (DR), one of the most common complications of diabetes. Stress due to persistent hyperglycaemia and corresponding glucotoxicity represents one of the primary pathogenic mechanisms of diabetes and its complications. Apoptosis of retinal neurons serves a critical role in the pathogenesis of DR observed in patients with diabetes and streptozotocin (STZ)­induced diabetic rats. Retinal neuron apoptosis occurs one month after STZ injection, which is considered the early stage of DR. The molecular mechanism involved in the suppression of retinal neuron apoptosis during the early stage of DR remains unclear. RNA­dependent protein kinase (PKR) is a stress­sensitive pro­apoptotic kinase. Our previous study indicated that PKR­associated protein X, a stress­sensitive activator of PKR, is upregulated in the early stage of STZ­induced diabetes. In order to assess the role of PKR in DR prior to apoptosis of retinal neurons, immunofluorescence and western blotting were performed to investigate the cellular localization and expression of PKR in the retina in the early stage of STZ­induced diabetes in rats. PKR activity was indirectly assessed by expression levels of phosphorylated eukaryotic translation initiation factor 2α (p­eIF2­α) and the presence of apoptotic cells in the retina was investigated by TUNEL assay. The findings revealed that PKR was localized in the nucleus of retinal ganglion and inner nuclear layer cells from normal and diabetic rats. To the best of our knowledge, the present study is the first to demonstrate nuclear localization of PKR in retinal neurons. Immunofluorescence analysis demonstrated that PKR was expressed in the nuclei of retinal neurons at 3 and 6 days and its expression was decreased at 15 days after STZ treatment. In addition, p­eIF2­α expression and cellular localization followed the trend of PKR, suggesting that this pro­apoptotic kinase was active in the nuclei of retinal neurons. These findings are consistent with the hypothesis that nuclear translocation of PKR may be a mechanism to sequester active PKR, thus preventing upregulation of cytosolic signalling pathways that induce apoptosis in retinal neurons. Apoptotic cells were not detected in the retina in the early stage of DR. A model was proposed to explain the mechanism by which apoptosis of retinal neurons by PKR is suppressed in the early stage of DR. The possible role of mitochondrial RNA (mtRNA) and Alu RNA in this phenomenon is also discussed since it was demonstrated that the cellular stress due to prolonged hyperglycaemia induces the release of mtRNA and transcription of Alu RNA. Moreover, it mtRNA activates PKR, whereas Alu RNA inhibits the activation of this protein kinase.


Sujet(s)
Diabète expérimental/métabolisme , Rétinopathie diabétique/métabolisme , Neurones rétiniens/métabolisme , eIF-2 Kinase/métabolisme , Animaux , Apoptose/génétique , Diabète expérimental/complications , Diabète expérimental/génétique , Rétinopathie diabétique/étiologie , Rétinopathie diabétique/génétique , Rétinopathie diabétique/anatomopathologie , Régulation négative , Facteur-2 d'initiation eucaryote/métabolisme , Mâle , Rat Wistar , Streptozocine , eIF-2 Kinase/génétique
8.
Int J Mol Sci ; 22(6)2021 Mar 21.
Article de Anglais | MEDLINE | ID: mdl-33801118

RÉSUMÉ

Diabetic retinopathy (DR) is one of the main causes of vision loss in the working age population. It is characterized by a progressive deterioration of the retinal microvasculature, caused by long-term metabolic alterations inherent to diabetes, leading to a progressive loss of retinal integrity and function. The mammalian retina presents an orderly layered structure that executes initial but complex visual processing and analysis. Gap junction channels (GJC) forming electrical synapses are present in each retinal layer and contribute to the communication between different cell types. In addition, connexin hemichannels (HCs) have emerged as relevant players that influence diverse physiological and pathological processes in the retina. This article highlights the impact of diabetic conditions on GJC and HCs physiology and their involvement in DR pathogenesis. Microvascular damage and concomitant loss of endothelial cells and pericytes are related to alterations in gap junction intercellular communication (GJIC) and decreased connexin 43 (Cx43) expression. On the other hand, it has been shown that the expression and activity of HCs are upregulated in DR, becoming a key element in the establishment of proinflammatory conditions that emerge during hyperglycemia. Hence, novel connexin HCs blockers or drugs to enhance GJIC are promising tools for the development of pharmacological interventions for diabetic retinopathy, and initial in vitro and in vivo studies have shown favorable results in this regard.


Sujet(s)
Connexines/métabolisme , Rétinopathie diabétique/étiologie , Rétinopathie diabétique/métabolisme , Prédisposition aux maladies , Jonctions communicantes/métabolisme , Animaux , Connexines/génétique , Rétinopathie diabétique/anatomopathologie , Jonctions communicantes/génétique , Expression des gènes , Humains , Névroglie/métabolisme , Rétine/métabolisme , Rétine/anatomopathologie
9.
Can J Diabetes ; 45(6): 504-511, 2021 Aug.
Article de Anglais | MEDLINE | ID: mdl-33341391

RÉSUMÉ

Diabetes mellitus (DM) is a chronic metabolic disorder characterized by impaired glucose homeostasis, insulin resistance and hyperglycemia. Among its serious multisystemic complications is diabetic retinopathy (DR), which develops slowly and often insidiously. This disorder-the most common cause of vision loss in working-age adults-is characterized by functional and morphological changes in the retina. It results from the exacerbation of ischemic and inflammatory conditions prompted by alterations in the blood vessels, such as the development of leukostasis, thickening of the basement membrane, retinal neovascularization and fibrovascular tissue formation at the vitreoretinal interface. The pathogenic alterations are usually triggered at the biochemical level, involving a greater activity in 4 pathways: the polyol pathway, the hexosamine pathway, the formation of advanced glycation end-products and the activation of protein kinase C isoforms. When acting together, these pathways give rise to increased levels of reactive oxygen species and decreased levels of endogenous antioxidant agents, thus generating oxidative stress. All current therapies are aimed at the later stages of DR, and their application implies side effects. One possible strategy for preventing the complications of DM is to counteract the elevated superoxide production stemming from a high level of blood glucose. Accordingly, some treatments are under study for their capacity to reduce vascular leakage and avoid retinal ischemia, retinal neovascularization and macular edema. The present review summarizes the biochemical aspects of DR and the main approaches for treating it.


Sujet(s)
Rétinopathie diabétique/métabolisme , Rétinopathie diabétique/thérapie , Phénomènes biochimiques , Humains
10.
Molecules ; 25(11)2020 May 31.
Article de Anglais | MEDLINE | ID: mdl-32486343

RÉSUMÉ

: Reactive nitrogen species (RNS) are formed when there is an abnormal increase in the level of nitric oxide (NO) produced by the inducible nitric oxide synthase (iNOS) and/or by the uncoupled endothelial nitric oxide synthase (eNOS). The presence of high concentrations of superoxide anions (O2-) is also necessary for their formation. RNS react three times faster than O2- with other molecules and have a longer mean half life. They cause irreversible damage to cell membranes, proteins, mitochondria, the endoplasmic reticulum, nucleic acids and enzymes, altering their activity and leading to necrosis and to cell death. Although nitrogen species are important in the redox imbalance, this review focuses on the alterations caused by the RNS in the cellular redox system that are associated with cardiometabolic diseases. Currently, nitrosative stress (NSS) is implied in the pathogenesis of many diseases. The mechanisms that produce damage remain poorly understood. In this paper, we summarize the current knowledge on the participation of NSS in the pathology of cardiometabolic diseases and their possible mechanisms of action. This information might be useful for the future proposal of anti-NSS therapies for cardiometabolic diseases.


Sujet(s)
Maladies cardiovasculaires/métabolisme , Monoxyde d'azote/métabolisme , Stress nitrosatif , Stress oxydatif , Animaux , Antioxydants/métabolisme , Mort cellulaire , Diabète/métabolisme , Rétinopathie diabétique/métabolisme , Réticulum endoplasmique/métabolisme , Endothélium vasculaire/métabolisme , Stéatose hépatique/métabolisme , Humains , Hypertension artérielle , Inflammation , Syndrome métabolique X/métabolisme , Mitochondries/métabolisme , Protéines mitochondriales/métabolisme , Nécrose , Obésité/métabolisme , Oxydoréduction , Oxygène/métabolisme , Espèces réactives de l'azote/métabolisme , Superoxydes/métabolisme
11.
Mitochondrion ; 52: 212-217, 2020 05.
Article de Anglais | MEDLINE | ID: mdl-32283307

RÉSUMÉ

Diabetic retinopathy is thought to be trigger by glucose- induced oxidative stress which leads to an increase of the mitochondrial permeability through opening the permeability transition pore (MTP). In several cell types, hexokinases interact with the mitochondria regulating MTP opening, avoiding cytochrome c release. We studied HK I mitochondrial proportion in control and streptozotocin-induced diabetic rat retinas. In the normal retina, 50% of HK I was linked to mitochondria, proportion that did not change up to 60 days of diabetes. Mitochondria from normal and diabetic rat retinas showed a limited swelling, and similar cytochrome c levels. G-6-P and glycogen content increased 3-6-fold in diabetic rat retinas, while lactate content did not vary. Results suggest that mitochondrial bound HK produce G-6-P and drove it to glycogen synthesis, controlling ROS production and lactate toxicity.


Sujet(s)
Diabète/induit chimiquement , Rétinopathie diabétique/métabolisme , Hexokinase/métabolisme , Rétine/métabolisme , Animaux , Cytochromes c/métabolisme , Diabète/métabolisme , Modèles animaux de maladie humaine , Femelle , Glucose-6-phosphate/métabolisme , Mitochondries/métabolisme , Rats , Streptozocine
12.
Int J Mol Sci ; 21(7)2020 Mar 28.
Article de Anglais | MEDLINE | ID: mdl-32231131

RÉSUMÉ

Diabetes produces several changes in the body triggered by high glycemia. Some of these changes include altered metabolism, structural changes in blood vessels and chronic inflammation. The eye and particularly the retinal ganglion cells (RGCs) are not spared, and the changes eventually lead to cell loss and visual function impairment. Understanding the mechanisms resulting in RGC damage and loss from diabetic retinopathy is essential to find an effective treatment. This review focuses mainly on the signaling pathways and molecules involved in RGC loss and the potential therapeutic approaches for the prevention of this cell death. Throughout the manuscript it became evident that multiple factors of different kind are responsible for RGC damage. This shows that new therapeutic agents targeting several factors at the same time are needed. Alpha-1 antitrypsin as an anti-inflammatory agent may become a suitable option for the treatment of RGC loss because of its beneficial interaction with several signaling pathways involved in RGC injury and inflammation. In conclusion, alpha-1 antitrypsin may become a potential therapeutic agent for the treatment of RGC loss and processes behind diabetic retinopathy.


Sujet(s)
Diabète/anatomopathologie , Rétinopathie diabétique/anatomopathologie , Cellules ganglionnaires rétiniennes/anatomopathologie , Animaux , Mort cellulaire , Diabète/traitement médicamenteux , Diabète/métabolisme , Rétinopathie diabétique/traitement médicamenteux , Rétinopathie diabétique/métabolisme , Humains , Inflammation/traitement médicamenteux , Inflammation/métabolisme , Inflammation/anatomopathologie , Thérapie moléculaire ciblée , Cellules ganglionnaires rétiniennes/effets des médicaments et des substances chimiques , Cellules ganglionnaires rétiniennes/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques
13.
Diabetes ; 69(3): 291-299, 2020 03.
Article de Anglais | MEDLINE | ID: mdl-32079705

RÉSUMÉ

The results of the Diabetes Control and Complications Trial (DCCT) have given rise to much encouragement in the battle to stave off the complications of type 1 diabetes, showing dramatic declines in the development of severe retinopathy, nephropathy, and neuropathy in those treated intensively compared with conventional therapy. Particularly encouraging has been the continuing difference between the two groups despite both having similar HbA1c (∼8%) since the end of DCCT, when 96% of participants entered the observational Epidemiology of Diabetes Interventions and Complications (EDIC) study. This continuing relative benefit has been termed "metabolic memory," which implies altered metabolic regulation. Based on evidence from both the Epidemiology of Diabetes Complications (EDC) prospective cohort study of childhood-onset type 1 diabetes and DCCT/EDIC, we show that the metabolic memory effect can be largely explained by lower cumulative glycemic exposure in the intensive therapy group, and, on average, the development of complications increases with greater glycemic exposure, irrespective of whether this results from a high exposure for a short time or a lower exposure for a longer time. Thus, there is no need for a concept like "metabolic memory" to explain these observations. Potential mechanisms explaining the cumulative glycemic effect are also briefly discussed.


Sujet(s)
Glycémie/métabolisme , Complications du diabète/prévention et contrôle , Diabète de type 1/traitement médicamenteux , Hémoglobine glyquée/métabolisme , Hypoglycémiants/usage thérapeutique , Insuline/usage thérapeutique , Études de cohortes , Complications du diabète/métabolisme , Diabète de type 1/complications , Diabète de type 1/métabolisme , Néphropathies diabétiques/métabolisme , Néphropathies diabétiques/prévention et contrôle , Neuropathies diabétiques/métabolisme , Neuropathies diabétiques/prévention et contrôle , Rétinopathie diabétique/métabolisme , Rétinopathie diabétique/prévention et contrôle , Humains , Planification des soins du patient , Études prospectives , Essais contrôlés randomisés comme sujet , Facteurs temps
14.
PLoS One ; 15(2): e0228895, 2020.
Article de Anglais | MEDLINE | ID: mdl-32032388

RÉSUMÉ

BACKGROUND: Alpha-1-antitrypsin is a protein involved in avoidance of different processes that are seen in diabetic retinopathy pathogenesis. These processes include apoptosis, extracellular matrix remodeling and damage of vessel walls and capillaries. Furthermore, because of its anti-inflammatory effects, alpha-1-antitrypsin has been proposed as a possible therapeutic approach for diabetic retinopathy. Our group tested alpha-1-antitrypsin in a type 1 diabetes mouse model and observed a reduction of inflammation and retinal neurodegeneration. Thus, shedding light on the mechanism of action of alpha-1-antitrypsin at molecular level may explain how it works in the diabetic retinopathy context and show its potential for use in other retinal diseases. METHODS: In this work, we evaluated alpha-1-antitrypsin in an ARPE-19 human cell line exposed to high glucose. We explored the expression of different mediators on signaling pathways related to pro-inflammatory cytokines production, glucose metabolism, epithelial-mesenchymal transition and other proteins involved in the normal function of retinal pigment epithelium by RT-qPCR and Western Blot. RESULTS: We obtained different expression patterns for evaluated mediators altered with high glucose exposure and corrected with the use of alpha-1-antitrypsin. CONCLUSIONS: The expression profile obtained in vitro for the evaluated proteins and mRNA allowed us to explain our previous results obtained on mouse models and to hypothesize how alpha-1-antitrypsin hinder diabetic retinopathy progression on a complex network between different signaling pathways. GENERAL SIGNIFICANCE: This network helps to understand the way alpha-1-antitrypsin works in diabetic retinopathy and its scope of action.


Sujet(s)
Rétinopathie diabétique/métabolisme , alpha-1-Antitrypsine/métabolisme , alpha-1-Antitrypsine/physiologie , Animaux , Apoptose/effets des médicaments et des substances chimiques , Lignée cellulaire , Rétinopathie diabétique/anatomopathologie , Modèles animaux de maladie humaine , Glucose/métabolisme , Humains , Inflammation/métabolisme , Souris , Facteur de transcription NF-kappa B/métabolisme , Rétine/métabolisme , Épithélium pigmentaire de la rétine/métabolisme , Épithélium pigmentaire de la rétine/physiologie , Transduction du signal/effets des médicaments et des substances chimiques , Facteur de nécrose tumorale alpha/métabolisme
15.
Invest Ophthalmol Vis Sci ; 60(12): 3842-3853, 2019 09 03.
Article de Anglais | MEDLINE | ID: mdl-31529081

RÉSUMÉ

Purpose: Outer blood retinal barrier breakdown is a neglected feature of diabetic retinopathy (DR). We demonstrated that the agonism of the δ opioid receptor (DOR) by epicatechin preserves the tight junction proteins in ARPE-19 cells under diabetic conditions. Presently, we aimed to evaluate the possible role of the DOR on the maintenance of tight junction of RPE layer and on the early markers of experimental DR. Methods: DR markers and external retinal tight junction proteins were evaluated in CL57B diabetic mice submitted to intravitreous injection of short hairpin RNA (shRNA)-DOR (108 transducing units [TU]/mL) treated or not with DOR agonist (0.05 g/animal/d of epicatechin in drinking water) for 16 weeks. The presence of DOR in human retina from postmortem eyes from diabetic and nondiabetic donors were also performed. Results: DOR is present in RPE layer and in neuro retina. The treatment with DOR agonist prevented the upregulation of the early markers of retinopathy (glial fibrillary acidic protein, VEGF) and the downregulation of pigment epithelium-derived factor, occludin, claudin-1, and zonula occludens-1 tight junction expressions. The silencing of DOR in retina of diabetic mice partially abolished the protective effects of epicatechin. In human retina specimens, DOR is present throughout the retina, similarly in nondiabetic and diabetic donors. Conclusions: This set of experiments strongly indicates that the DOR agonism preserves RPE tight junctions and reduces the early markers of retinopathy in model of diabetes. These novel findings designate DOR as a potential therapeutic tool to treat DR with preservation of the RPE tight junction proteins.


Sujet(s)
Catéchine/pharmacologie , Diabète expérimental/prévention et contrôle , Rétinopathie diabétique/prévention et contrôle , Récepteur delta/agonistes , Épithélium pigmentaire de la rétine/métabolisme , Jonctions serrées/métabolisme , Sujet âgé , Animaux , Glycémie/métabolisme , Technique de Western , Claudine-1/métabolisme , Diabète expérimental/métabolisme , Rétinopathie diabétique/métabolisme , Rétinopathie diabétique/anatomopathologie , Impédance électrique , Protéines de l'oeil/métabolisme , Femelle , Technique d'immunofluorescence indirecte , Protéine gliofibrillaire acide/métabolisme , Humains , Immunohistochimie , Mâle , Souris , Souris de lignée C57BL , Adulte d'âge moyen , Facteurs de croissance nerveuse/métabolisme , Occludine/métabolisme , Petit ARN interférent , Réaction de polymérisation en chaine en temps réel , Récepteur delta/métabolisme , Serpines/métabolisme , Facteur de croissance endothéliale vasculaire de type A/métabolisme , Protéine-1 de la zonula occludens/métabolisme
16.
J Diabetes Res ; 2019: 8562408, 2019.
Article de Anglais | MEDLINE | ID: mdl-31511825

RÉSUMÉ

Diabetic retinopathy (DR) is one of the most common complications of diabetes mellitus (DM) causing vision impairment even at young ages. There are numerous mechanisms involved in its development such as inflammation and cellular degeneration leading to endothelial and neural damage. These mechanisms are interlinked thus worsening the diabetic retinopathy outcome. In this review, we propose oxidative stress as the focus point of this complication onset.


Sujet(s)
Antioxydants/usage thérapeutique , Rétinopathie diabétique/traitement médicamenteux , Rétinopathie diabétique/étiologie , Stress oxydatif/physiologie , Animaux , Diabète/métabolisme , Diabète/anatomopathologie , Rétinopathie diabétique/métabolisme , Évolution de la maladie , Humains , Facteurs de risque , Vision/effets des médicaments et des substances chimiques , Vision/physiologie
17.
Lipids Health Dis ; 18(1): 114, 2019 May 15.
Article de Anglais | MEDLINE | ID: mdl-31092270

RÉSUMÉ

Vision disorders are one of the most serious complications of diabetes mellitus (DM) affecting the quality of life of patients and eventually cause blindness. The ocular lesions in diabetes mellitus are located mainly in the blood vessels and retina layers. Different retina lesions could be grouped under the umbrella term of diabetic retinopathies (DMRP).We propose that one of the main causes in the etiopathogenesis of the DMRP consists of a progressive loss of the selective permeability of blood retinal barriers (BRB). The loss of selective permeability of blood retinal barriers will cause a progressive autoimmune process. Prolonged autoimmune injures in the retinal territory will triggers and maintains a low-grade chronic inflammation process, microvascular alterations, glial proliferation and subsequent fibrosis and worse, progressive apoptosis of the photoreceptor neurons.Patients with long-standing DM disturbances in retinal BRBs suffer of alterations in the enzymatic pathways of polyunsaturated fatty acids (PUFAs), increase release of free radicals and pro-inflammatory molecules and subsequently incremented levels of vascular endothelial growth factor. These facts can produce retinal edema and photoreceptor apoptosis.Experimental, clinical and epidemiological evidences showing that adequate metabolic and alimentary controls and constant practices of healthy life may avoid, retard or make less severe the appearance of DMRP. Considering the high demand for PUFAs ω3 by photoreceptor complexes of the retina, it seems advisable to take fish oil supplements (2 g per day). The cellular, subcellular and molecular basis of the propositions exposed above is developed in this article.Synthesizer drawings the most relevant findings of the ultrastructural pathology, as well as the main metabolic pathways of the PUFAs involved in balance and disbalanced conditions are provided.


Sujet(s)
Auto-immunité , Barrière hématorétinienne/métabolisme , Barrière hématorétinienne/anatomopathologie , Rétinopathie diabétique/immunologie , Rétinopathie diabétique/métabolisme , Acides gras omega-3/métabolisme , Inflammation/anatomopathologie , Animaux , Rétinopathie diabétique/anatomopathologie , Directives de santé publique , Humains
18.
Exp Eye Res ; 184: 243-257, 2019 07.
Article de Anglais | MEDLINE | ID: mdl-31059692

RÉSUMÉ

Chronic hyperglycemia, oxidative stress and inflammation are key players in the pathogenesis of diabetic retinopathy (DR). In this work we study the role of phospholipase D (PLD) pathway in an in vitro model of high glucose (HG)-induced damage. To this end, we exposed human retinal pigment epithelium (RPE) cell lines (ARPE-19 and D407) to HG concentrations (16.5 or 33 mM) or to normal glucose concentration (NG, 5.5 mM) for 4, 24 or 72 h. Exposure to HG increased reactive oxygen species levels and caspase-3 cleavage and reduced cell viability after 72 h of incubation. In addition, short term HG exposure (4 h) induced the activation of early events, that involve PLD and ERK1/2 signaling, nuclear factor kappa B (NFκB) nuclear translocation and IκB phosphorylation. The increment in pro-inflammatory interleukins (IL-6 and IL-8) and cyclooxygenase-2 (COX-2) mRNA levels was observed after 24 h of HG exposure. The effect of selective pharmacological PLD1 (VU0359595) and PLD2 (VU0285655-1) inhibitors demonstrated that ERK1/2 and NFκB activation were downstream events of both PLD isoforms. The increment in IL-6 and COX-2 mRNA levels induced by HG was reduced to control levels in cells pre-incubated with both PLD inhibitors. Furthermore, the inhibition of PLD1, PLD2 and MEK/ERK pathway prevented the loss of cell viability and the activation of caspase-3 induced by HG. In conclusion, our findings demonstrate that PLD1 and PLD2 mediate the inflammatory response triggered by HG in RPE cells, pointing to their potential use as a therapeutic target for DR treatment.


Sujet(s)
Rétinopathie diabétique/métabolisme , Glucose/pharmacologie , Phospholipase D/métabolisme , Épithélium pigmentaire de la rétine/effets des médicaments et des substances chimiques , Technique de Western , Caspase-3/métabolisme , Lignée cellulaire , Cyclooxygenase 2/génétique , Extracellular Signal-Regulated MAP Kinases/métabolisme , Humains , Interleukine-6/génétique , Interleukine-8/génétique , Microscopie confocale , Microscopie de fluorescence , Stress oxydatif , Phosphorylation , Protein-Serine-Threonine Kinases/métabolisme , ARN messager/génétique , Espèces réactives de l'oxygène/métabolisme , Réaction de polymérisation en chaine en temps réel , Épithélium pigmentaire de la rétine/métabolisme , NF-kappaB-Inducing Kinase
19.
Acta Diabetol ; 56(9): 1031-1036, 2019 Sep.
Article de Anglais | MEDLINE | ID: mdl-30982154

RÉSUMÉ

AIMS: Retinopathy is a leading cause of vision impairment in diabetes. Its pathogenesis involves inflammation, pathological angiogenesis, neuronal and glial dysfunction. The purinergic P2X7 receptor (P2X7R) has a leading role in inflammation and angiogenesis. Potent and selective P2X7R blockers have been synthesized and tested in Phase I/II clinical studies. We hypothesize that P2X7R blockade will ameliorate diabetes-related pathological retinal changes. METHODS: Streptozotocin (STZ)-treated rats were intraperitoneally inoculated with either of two small molecule P2X7R receptor inhibitors, A740003 and AZ10606120, and after blood glucose levels increased to above 400 mg/dL, retinae were analyzed for P2X7R expression, vascular permeability, VEGF, and IL-6 expression. RESULTS: STZ administration caused a near fourfold increase in blood glucose, a large increase in retinal microvasculature permeability, as well as in retinal P2X7R, VEGF, and IL-6 expression. P2X7R blockade fully reversed retinal vascular permeability increase, VEGF accumulation, and IL-6 expression, with no effect on blood glucose. CONCLUSION: P2X7R blockade might be promising strategy for the treatment of microvascular changes observed in the early phases of diabetic retinopathy.


Sujet(s)
Diabète de type 1/complications , Diabète de type 1/traitement médicamenteux , Rétinopathie diabétique/prévention et contrôle , Antagonistes des récepteurs purinergiques P2X/pharmacologie , Rétine/effets des médicaments et des substances chimiques , Animaux , Glycémie/effets des médicaments et des substances chimiques , Glycémie/métabolisme , Diabète expérimental/complications , Diabète expérimental/traitement médicamenteux , Diabète expérimental/métabolisme , Diabète expérimental/anatomopathologie , Diabète de type 1/anatomopathologie , Rétinopathie diabétique/traitement médicamenteux , Rétinopathie diabétique/métabolisme , Inflammation/complications , Inflammation/traitement médicamenteux , Inflammation/métabolisme , Mâle , Névroglie/effets des médicaments et des substances chimiques , Névroglie/métabolisme , Névroglie/anatomopathologie , Rats , Rat Wistar , Récepteurs purinergiques P2X7/métabolisme , Rétine/métabolisme , Rétine/anatomopathologie , Streptozocine , Résultat thérapeutique
20.
Arq. bras. oftalmol ; Arq. bras. oftalmol;82(2): 136-140, Mar.-Apr. 2019. tab, graf
Article de Anglais | LILACS | ID: biblio-989397

RÉSUMÉ

ABSTRACT Purpose: We aimed to compare the aqueous humor total oxidant status, total antioxidant capacity, and levels of interleukin-6 and vascular endothelial growth factor between patients with diabetic retinopathy and controls and to correlate these levels with the DR status. Methods: Patients who underwent cataract surgery were enrolled. The first group (control group) comprised patients without diabetes; the second group comprised diabetic patients without retinopathy; the third group comprised patients with nonproliferative diabetic retinopathy; and the fourth group comprised patients with proliferative diabetic retinopathy. All patients underwent full ophthalmologic examination before cataract surgery. Prior to surgery, samples of aqueous humor sampling were obtained and stored at -80 °C. Total antioxidant capacity, total oxidant status, and levels interleukin-6 and vascular endothelial growth factor were investigated in these samples and correlated with diabetic retinopathy status. Results: This study analyzed 86 pairs of eyes of 86 patients. All groups were statistically similar in age and sex, but the total antioxidant capacity was lowest in patients with proliferative diabetic retinopathy. Moreover, the total oxidant status and levels of vascular endothelial growth factor and interleukin-6 were found to slightly increase according to the retinopathy status. Conclusion: Oxidative stress, interleukin-6, and vascular endothelial growth factor in the aqueous humor seem to play important roles in the pathogenesis of diabetic retinopathy, especially in the proliferative type.


RESUMO Objetivo: Procurou-se comparar o humor aquoso estado oxidante total, a capacidade antioxidante total, e os níveis de interleucina-6 e do fator de crescimento endotelial vascular entre pacientes com retinopatia diabética e em indivíduos controles, e correlacionar esses níveis com o status da retinopatia diabética. Métodos: Pacientes submetidos à cirurgia de catarata foram incluídos. O primeiro grupo (grupo controle) foi composto por pacientes sem diabetes; o segundo grupo inclui pacientes dia béticos sem retinopatia; o terceiro grupo inclui pacientes com retinopatia diabética não proliferativa; e o quarto grupo inclui pacientes com retinopatia diabética proliferativa. Todos os pacientes foram submetidos a exame oftalmológico completo antes da cirurgia de catarata. Antes da cirurgia, amostras de humor aquoso foram obtidas e armazenadas a -80oC. A capacidade antioxidante total, o estado oxidante total e os níveis de interleucina-6 e fator de crescimento endotelial vascular foram investigados nessas amostras e correlacionados com o status da retinopatia diabética. Resultados: Este estudo analisou 86 pares de olhos de 86 pacientes. Todos os grupos foram estatisticamente semelhantes em idade e sexo, mas a capacidade antioxidante total foi menor em pacientes com retinopatia diabética proliferativa. Além disso, o estado oxidante total e os níveis de fator de crescimento endotelial vascular e interleucina-6 estavam ligeiramente aumentados de acordo com o status da retinopatia. Conclusão: O estresse oxidativo, a interleucina-6 e o fator de crescimento endotelial vascular no humor aquoso parecem desempenhar papel importante na patogênese da retinopatia diabética, especialmente no tipo proliferativo.


Sujet(s)
Humains , Mâle , Femelle , Adulte d'âge moyen , Sujet âgé , Humeur aqueuse/métabolisme , Interleukine-6/analyse , Stress oxydatif , Facteur de croissance endothéliale vasculaire de type A/analyse , Rétinopathie diabétique/métabolisme , Antioxydants/analyse , Valeurs de référence , Hémoglobine glyquée/analyse , Test ELISA , Études cas-témoins , Études prospectives , Chromatographie en phase liquide à haute performance , Statistique non paramétrique , Antioxydants/métabolisme
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE